Small molecule biomarker discovery: Proposed workflow for LC-MS-based clinical research projects

Area of Science:

• Biomarker Discovery
• Clinical Research
• Personalized Medicine

Background:

• Mass spectrometry, particularly for small endogenous molecules, is crucial for understanding disease pathophysiology.
• Liquid chromatography-mass spectrometry (LC-MS) generates large datasets essential for biomarker discovery.
• Clinical research requires collaboration between researchers, clinicians, and data scientists.

Purpose of the Study:

• To provide a comprehensive overview of conducting LC-MS-based clinical research for small molecule biomarker discovery.
• To guide researchers through the various stages of a clinical research project.
• To emphasize the importance of interdisciplinary collaboration and quality control.

Main Methods:

• Study design and planning, including scope definition and expert engagement.
• Subject enrollment and trial design considering epidemiological factors.
• Pre-analytical sample handling, LC-MS measurement (targeted, semi-targeted, non-targeted), and data processing.
• In-silico analysis using classical statistics, machine learning, pathway analysis, and gene set enrichment.
• Validation of results and implementation of quality control measures throughout the study.

Main Results:

• Successful biomarker discovery necessitates meticulous planning and execution.
• Data quality is heavily influenced by pre-analytical sample handling and analytical methods.
• Robust data analysis requires a combination of statistical and machine learning approaches.
• Interdisciplinary collaboration is vital for translating research findings into clinical applications.

Conclusions:

• LC-MS is a powerful tool for identifying small molecule biomarkers in clinical research.
• A systematic approach, from study design to validation, ensures reliable results.
• Effective communication and collaboration among stakeholders are critical for success.
• Implementing rigorous quality control enhances the confidence in diagnostic and prognostic biomarkers.